Diabetes Drug Mounjaro Shows Unexpected Impact on Alcohol Consumption

Scientists from the University of Gothenburg have reported that tirzepatide — the active compound in the diabetes and weight-loss medication Mounjaro - markedly reduced alcohol consumption in laboratory animals. The findings, published in eBioMedicine, indicate that the substance may influence neural mechanisms associated with reward and reinforcement. Alcohol Intake Fell by More Than Half In experiments involving rats and mice, researchers observed that voluntary alcohol consumption declined by more than twofold when animals received tirzepatide. The reduction appeared consistently across multiple experimental scenarios, including prolonged voluntary drinking, binge-like patterns, and models designed to mimic relapse behavior. Typically, animals increase alcohol intake after a period without access. However, this pattern did not emerge in the tirzepatide-treated groups. Instead, alcohol consumption fell below baseline levels, suggesting that the compound altered the expected rebound effect following abstinence.